Navigation Links
WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering
Date:1/20/2012

LOS ANGELES, Jan. 20, 2012 /PRNewswire/ -- WestPark Capital, Inc. announced the initial closing of a private placement for Arrogene NanoTechnology, Inc. on January 10, 2012.  A total of 500,000 Units, each Unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds of approximately $500,000.  Proceeds from the offering will be used for working capital and research and development related to Arrogene's diagnostic and therapeutic technologies for brain, breast and lung cancer.  WestPark Capital, Inc. acted as placement agent for the offering.

This news release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful.  The offering was made only by Confidential Private Placement Memorandum.  Copies of the Confidential Private Placement Memorandum may be obtained via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

About WestPark Capital, Inc.

WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide.  WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them.  WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services.  Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at info@wpcapital.com. Member: FINRA/SIPC

About Arrogene NanoTechnology, Inc.

Arrogene NanoTechnology is developing a n
'/>"/>

SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. WestPark Capital Announces $2.6 Million IsoRay Offering
2. WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
3. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MUMBAI , Indien, August 1, 2014 ... ("Cipla") und BioQuiddity Inc. gaben heute bekannt, ... in regionalen Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen ... die das Gebiet der Europäischen Union und ... mit CE-Kennzeichnung versehene und mit Ropivacain gefüllte ...
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today reported financial ... 28, 2014.  , Revenues were $10.6 million in ... in the 2013 second quarter and up sequentially from $10.3 ... first six months of 2014 were $20.9 million, up 15% ... year. , Gross margin for the quarter was 50.0%, ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant,s subsidiaries, Valeant Pharmaceuticals North America LLC ... signed an agreement to acquire the assets of ...  Valeant will pay Janssen $345 million for the ...
... Aethlon Medical, Inc., (OTCBB: AEMD) disclosed today that ... the following letter to shareholders. (Photo: ... Last December, I authored a shareholder letter which ... need for innovative new therapeutic strategies to evolve as ...
Cached Medicine Technology:Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics 2Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics 3Aethlon Medical Releases Shareholder Letter 2Aethlon Medical Releases Shareholder Letter 3Aethlon Medical Releases Shareholder Letter 4
(Date:8/1/2014)... NJ (PRWEB) August 01, 2014 ... web portal that aims to empower patients and ... in their health care by providing easy, secure ... Portal gives patients instant, web-based access to their ... and radiology results, medications, allergies, demographic information, visit ...
(Date:8/1/2014)... procedures have grown in popularity as more and more ... toxin generally known as BOTOX use ... have emerged to perform procedures utilizing this and other ... from the Division of Plastic Surgery Presbyterian Hospital in ... University in New York have assessed the capability of ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 St. Christopher's ... in an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , St. Christopher's Hospital ... services for children from birth through 21 years of ... several of the hospital's specialties, including autism and childhood ...
(Date:8/1/2014)... Narconon Arrowhead recently celebrated the occasion ... drug rehab center located in the small town of ... is the flagship drug rehab center in the Narconon ... for services there. Now, with such a long track ... as well as client reviews showing the effectiveness of ...
(Date:8/1/2014)... TX (PRWEB) August 01, 2014 Delta ... the Year for its outstanding commitment to St. Jude ... the hospital since 1999 and pledging to raise another ... combat childhood cancer and other deadly diseases. , ... any single partner in St. Jude history. Specifically, it ...
Breaking Medicine News(10 mins):Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 2Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 3
... disorder (ADHD) is one of the most common mental ... are excessively restless, impulsive, and distractible and experience difficulties ... a common theme for ADHD symptoms. These symptoms ... a combination of the two. In a ...
... number of women delaying motherhood until their 40s grows, CDC ... going up in both 2005 and 2006, the number of ... 2008, federal health officials report. , On the other hand, ... life, with a big jump in births for women in ...
... Human Touch Massage ... , ... 6, 2010 -- Human Touch , the U.S. market leader of innovative massage chairs, ... Federation of Chiropractic (WFC) for its massage chairs as a valid supplement to back-care therapies. ...
... is available in German . This ... Forschungsgemeinschaft (DFG, German Research Foundation) and the Donors, Association ... (Stifterverband fr die Deutsche Wissenschaft) goes to cell physiologist ... professor at Bochum,s Ruhr University for his many years ...
... ... “Federal Cyber Security Outlook for 2010” Provides In-Depth Dive into Endpoint Management and Cyber ... ... new Clarus Research Group survey commissioned by Lumension , nearly three-quarters of federal ...
... sedatives up 65 percent in U.S., study finds , ... accidental and intentional abuse of prescription sedatives, tranquilizers and ... decade, new research reveals. , Hospital stays from an ... and sedatives (such as Valium and Ativan) jumped 37 ...
Cached Medicine News:Health News:Synergy between behavioral and pharmacologic interventions for ADHD 2Health News: U.S. Teen Birth Rate Drops 2Health News: U.S. Teen Birth Rate Drops 3Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 2Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 3Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 4Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 5Health News:Communicator Award 2010 goes to Hanns Hatt 2Health News:Communicator Award 2010 goes to Hanns Hatt 3Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 2Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 3Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 4Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 5Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 6Health News:Prescription Drug Abuse Sending More to Hospitals 2Health News:Prescription Drug Abuse Sending More to Hospitals 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: